Unlike other IMiDs or CELMoDs, avadomide degrades ZNF198 (or ZMYM2) fusion oncoproteins, such as ZNYM2-FGFR1 and ZMYM2-FLT3, indicating potential benefit for patients with acute lymphoblastic leukemias harboring these translocations [13]. The gene discussed is ZMYM2; the disease is acute lymphoblastic leukemia.